Information Provided By:
Fly News Breaks for September 10, 2015
HTWR
Sep 10, 2015 | 08:10 EDT
Canaccord said the weakness in HeartWare following its announcement of a pause of trial enrollment in their ongoing MVAD CE Mark clinical trial is a buying opportunity. The firm said the delay was due to assembly issues in the controller manufacturing process but the pause in enrollment was voluntary and as a result they remain bullish. Canaccord reiterated its Buy rating and $106 price target on HeartWare shares.
News For HTWR From the Last 2 Days
There are no results for your query HTWR